Search Results - "Angiolillo, Dominick J."

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis by Galli, Mattia, Benenati, Stefano, Capodanno, Davide, Franchi, Francesco, Rollini, Fabiana, D'Amario, Domenico, Porto, Italo, Angiolillo, Dominick J

“…Whether guided selection of antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) is effective in improving outcomes compared…”
Get full text

Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management by Ortega-Paz, Luis, Capodanno, Davide, Montalescot, Gilles, Angiolillo, Dominick J

“…Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2, which has posed a significant threat to…”
Get full text

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention by Sibbing, Dirk, Aradi, Daniel, Alexopoulos, Dimitrios, ten Berg, Jurrien, Bhatt, Deepak L., Bonello, Laurent, Collet, Jean-Philippe, Cuisset, Thomas, Franchi, Francesco, Gross, Lisa, Gurbel, Paul, Jeong, Young-Hoon, Mehran, Roxana, Moliterno, David J., Neumann, Franz-Josef, Pereira, Naveen L., Price, Matthew J., Sabatine, Marc S., So, Derek Y.F., Stone, Gregg W., Storey, Robert F., Tantry, Udaya, Trenk, Dietmar, Valgimigli, Marco, Waksman, Ron, Angiolillo, Dominick J.

“…Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary…”
Get full text

Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients by Cao, Davide, Mehran, Roxana, Dangas, George, Baber, Usman, Sartori, Samantha, Chandiramani, Rishi, Stefanini, Giulio G, Angiolillo, Dominick J, Capodanno, Davide, Urban, Philip, Morice, Marie-Claude, Krucoff, Mitchell, Goel, Ridhima, Roumeliotis, Anastasios, Sweeny, Joseph, Sharma, Samin K, Kini, Annapoorna

“…Bleeding following percutaneous coronary intervention has important prognostic implications. The Academic Research Consortium (ARC) recently proposed a list of…”
Get full text

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials by Galli, Mattia, Benenati, Stefano, Franchi, Francesco, Rollini, Fabiana, Capodanno, Davide, Biondi-Zoccai, Giuseppe, Vescovo, Giovanni Maria, Cavallari, Larisa H, Bikdeli, Behnood, ten Berg, Jurrien, Mehran, Roxana, Gibson, Charles Michael, Crea, Filippo, Pereira, Naveen L, Sibbing, Dirk, Angiolillo, Dominick J

“…Abstract Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary…”
Get full text

Clinical Pharmacokinetics and Pharmacodynamics of CSL112 by Ortega-Paz, Luis, Giordano, Salvatore, Capodanno, Davide, Mehran, Roxana, Gibson, C. Michael, Angiolillo, Dominick J.

“…Cardiovascular diseases are the leading cause of death worldwide. Although there have been substantial advances over the last decades, recurrent adverse…”
Get full text

Antithrombotic therapy for acute coronary syndrome: Past, present and future by Sibbing, Dirk, Angiolillo, Dominick J, Huber, Kurt

“…Plaque erosions and ruptures are the histopathological hallmarks of arterial thrombus formation in the coronary arteries. The clinical condition associated…”
Get more information

Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome by FERREIRO, Jose Luis, ANGIOLILLO, Dominick J

Get full text

Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy by Moon, Jae Youn, Franchi, Francesco, Rollini, Fabiana, Angiolillo, Dominick J.

“…Dual antiplatelet therapy (DAPT) has represented for decades the cornerstone of treatment for the prevention of ischemic complications, including stent…”
Get full text

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention by Aradi, Dániel, Kirtane, Ajay, Bonello, Laurent, Gurbel, Paul A, Tantry, Udaya S, Huber, Kurt, Freynhofer, Matthias K, ten Berg, Jurrien, Janssen, Paul, Angiolillo, Dominick J, Siller-Matula, Jolanta M, Marcucci, Rossella, Patti, Giuseppe, Mangiacapra, Fabio, Valgimigli, Marco, Morel, Olivier, Palmerini, Tullio, Price, Matthew J, Cuisset, Thomas, Kastrati, Adnan, Stone, Gregg W, Sibbing, Dirk

“…Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds…”
Get full text

Antithrombotic Therapy in the Elderly by Capodanno, Davide, MD, Angiolillo, Dominick J., MD, PhD

“…Antithrombotic therapy represents the mainstay of treatment for prevention of recurrent ischemic events in patients with atherothrombotic disease processes…”
Get full text

Basic Principles of Platelet Biology and Clinical Implications by Angiolillo, Dominick J., Ueno, Masafumi, Goto, Shinya

“…Platelet activation and subsequent accumulation at sites of vascular injury are the first steps in hemostasis. Excessive platelet activation after…”
Get full text

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding by Tantry, Udaya S., PhD, Bonello, Laurent, MD, PhD, Aradi, Daniel, MD, PhD, Price, Matthew J., MD, Jeong, Young-Hoon, MD, PhD, Angiolillo, Dominick J., MD, PhD, Stone, Gregg W., MD, Curzen, Nick, BM (hons), PhD, Geisler, Tobias, MD, ten Berg, Jurrien, MD, PhD, Kirtane, Ajay, MD, SM, Siller-Matula, Jolanta, MD, PhD, Mahla, Elisabeth, MD, Becker, Richard C., MD, Bhatt, Deepak L., MD, MPH, Waksman, Ron, MD, Rao, Sunil V., MD, Alexopoulos, Dimitrios, MD, Marcucci, Rossella, MD, PhD, Reny, Jean-Luc, MD, PhD, Trenk, Dietmar, PhD, Sibbing, Dirk, MD, Gurbel, Paul A., MD

“…Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in…”
Get full text

De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when? by Galli, Mattia, Angiolillo, Dominick J

“…The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1 blockade and P2Y signaling by combining aspirin plus a potent P2Y inhibitor…”
Get full text

Clopidogrel–Drug Interactions by Bates, Eric R., MD, Lau, Wei C., MD, Angiolillo, Dominick J., MD, PhD

“…Multidrug therapy increases the risk for drug–drug interactions. Clopidogrel, a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce…”
Get full text

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus by Bhatt, Deepak L., MD, MPH, Grosser, Tilo, MD, Dong, Jing-fei, MD, PhD, Logan, Douglas, MD, Jeske, Walter, PhD, Angiolillo, Dominick J., MD, PhD, Frelinger, Andrew L., PhD, Lei, Lanyu, MSc, Liang, Juan, PhD, Moore, Jason E., MS, Cryer, Byron, MD, Marathi, Upendra, PhD

“…Abstract Background A limitation of aspirin is that some patients, particularly those with diabetes, may not have an optimal antiplatelet effect. Objectives…”
Get full text

Antiplatelet Therapy in Diabetes : Efficacy and Limitations of Current Treatment Strategies and Future Directions by ANGIOLILLO, Dominick J

“…[...] although this indication in the general population is controversial, there is an expert consensus for aspirin usage in the primary prevention setting in…”
Get full text

Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes by Greco, Antonio, Laudani, Claudio, Occhipinti, Giovanni, Angiolillo, Dominick J, Capodanno, Davide

Get full text

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease by Capodanno, Davide, Bhatt, Deepak L., Eikelboom, John W., Fox, Keith A. A., Geisler, Tobias, Michael Gibson, C., Gonzalez-Juanatey, Jose Ramon, James, Stefan, Lopes, Renato D., Mehran, Roxana, Montalescot, Gilles, Patel, Manesh, Steg, P. Gabriel, Storey, Robert F., Vranckx, Pascal, Weitz, Jeffrey I., Welsh, Robert, Zeymer, Uwe, Angiolillo, Dominick J.

“…Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks…”
Get full text

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives by De Luca, Leonardo, Steg, Philippe Gabriel, Bhatt, Deepak L., Capodanno, Davide, Angiolillo, Dominick J.

“…Abstract Cangrelor is the only currently available intravenous platelet P2Y 12 receptor inhibitor. It is characterized by potent, predictable, and rapidly…”
Get full text